Literature DB >> 10399863

Cyclosporine neurotoxicity: a review.

J M Gijtenbeek1, M J van den Bent, C J Vecht.   

Abstract

Cyclosporin A (CsA) induces neurological side effects in up to 40% of patients. A reversible posterior leukoencephalopathy syndrome is the most serious complication. Symptoms include headache, altered mental functioning, seizures, cortical blindness, and other visual disturbances, with hypertension. Neuroimaging studies show white matter changes in the posterior regions of the brain. Other neurological side effects of CsA include tremor, diffuse encephalopathy, cerebellar syndrome, extrapyramidal syndrome, pyramidal weakness, and peripheral neuropathy. Hypertension, hypomagnesemia, hypocholesteremia, and the vasoactive agent endothelin may all play a role in the pathogenesis of CsA neurotoxicty. Neurotoxicity is more frequent with high CsA blood levels, but levels may be within the therapeutic range. Dose reduction or withdrawal of CsA usually results in resolution of clinical symptoms and of neuroimaging abnormalities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399863     DOI: 10.1007/s004150050360

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  99 in total

1.  Involvement of glial cells in cyclosporine-increased permeability of brain endothelial cells.

Authors:  S Dohgu; Y Kataoka; H Ikesue; M Naito; T Tsuruo; R Oishi; Y Sawada
Journal:  Cell Mol Neurobiol       Date:  2000-12       Impact factor: 5.046

Review 2.  Neuropsychiatric complications of liver transplantation.

Authors:  A Stracciari; M Guarino
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

3.  Once-a-day oral dosing regimen of cyclosporin A: combined therapy of cyclosporin A premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates.

Authors:  C K Kim; H J Shin; S G Yang; J H Kim; Y K Oh
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

4.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

5.  Vasospasm is a significant factor in cyclosporine-induced neurotoxicity: case report.

Authors:  Hilde M H Braakman; Jan Lodder; Alida A Postma; Lambert F R Span; Werner H Mess
Journal:  BMC Neurol       Date:  2010-05-11       Impact factor: 2.474

Review 6.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

7.  Analysis of cyclosporin A-induced reversible cortical blindness by diffusion-weighted magnetic resonance imaging techniques.

Authors:  Shin-ichi Manabe; Satoshi Kashii; Yukio Miki; Yoshihito Honda
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

8.  Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.

Authors:  W S Bartynski; J F Boardman; Z R Zeigler; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

9.  Posterior Reversible Encephalopathy Syndrome: The Spectrum of MR Imaging Patterns.

Authors:  O Kastrup; M Schlamann; C Moenninghoff; M Forsting; S Goericke
Journal:  Clin Neuroradiol       Date:  2014-02-20       Impact factor: 3.649

10.  Prolonged reversible vasospasm in cyclosporin A-induced encephalopathy.

Authors:  Jen-Tsun Lin; Shuu-Jiun Wang; Jong-Ling Fuh; Lian-Tsai Hsiao; Jiing-Feng Lirng; Po-Min Chen
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.